THE TAPE

Silence Therapeutics Plc American Depository Share

$19.80▼ −0.15%
Last close
Relative strength
99RS
of 99, against every stock▲ +37 on the month
Powering up
Developing
+186.1%
six months against Pharmaceutical Preparations
52-week range
−0.3%
from the high
$4.19$19.86
Setup
vcpforming
−0.3%
against the pivot at $19.86
No report date on the calendar.
Growth WEAKProof PENDING
Quarter to Jun 30, revenue −100% on a year ago
11/16 O 19.80 H 19.83 L 19.80 Vol 625.5K
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

All four are in order, fastest above slowest — every timeframe pointing the same way.

RS99
vs pivot−0.33%
Tightening1.42×
Dry-up2.07×
Up/down vol0.61
From high0%
forming9 of 9checks
Previous breakout still open ▲ +1.12% in Oct
Powering up
Support and resistance
Support below
None within the last 120 sessions
Resistance above
None within the last 120 sessions

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 3.2 weeks and fell 1% from its ceiling at its deepest. The pivot is $19.86, and the stock closed 0.3% below it. Its relative strength rating is 99.

Against its industry
DevelopingAhead of its industry over one and three months and not behind over six, in an industry at least partly aligned.
One month against its industry
+118.4%
Three months against its industry
+62.3%
Six months against its industry
+186.1%

Read against an equal-weighted index of Pharmaceutical Preparations, which is +10.9% against the S&P 500 over six months Partly aligned.

Peers
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 9.1% either way across its last 7 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$615.0K
-100.0% year on year
Operating margin
-11106.8%
gross 85.9%
Net margin
-9748.1%
Free cash flow
$-42.3M
-3.4% of market cap
Price to sales
2002.6×
Price to earnings
—
not meaningful on a loss

Twelve months to Jun 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules
Key takeaway
Revenue is falling but the business still generates cash.
Revenue
—
-100.0% QoQ · -100.0% YoY
Gross margin
—
Net income
−$12.3M
Loss
Free cash flow
$1.5M
Cash generating

What the numbers say

  • Weak: Revenue -100.0% year over year, -100.0% on the quarter
  • Weak: Net loss $12M, narrower than $15M last quarter
  • Good: Cash generating: operating cash flow $2M, free cash flow $2M
  • Good: Net cash $72M · cash $72M
Revenue by quarter
Free cash flow
Net income
shares 0.0% in a year · net cash $72.1M

What is not obvious

  • Weak: Stock compensation $1M added back, 86% of operating cash flow; $210K after it
Final read
Growth: WEAK · Economic proof: PENDING
Key question: What turns the cash flow positive?
The next test is revenue growth: revenue -100.0% year over year, -100.0% on the quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 1 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 bought new.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Reported resultsFiling · 2026-11-13
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Tightening after a sharp runTape · 2026-11-03
range halved after a +128% thrust, at 19.76
No measurable effect: stocks behave like random ones over the next three sessions (887 cases over 60 nights).
New 52-week highTape · 2026-10-21
4.1x vol
Mixed: stocks have lagged random stocks by 0.9% over three sessions, not consistently enough to call (554 cases over 52 nights). Against their own sector they have lagged by 2.1%.
Red flag in a filingFiling · 2026-10-20
material weakness;resignation of
No measurable effect: stocks behave like random ones over the next three sessions (1,160 cases over 54 nights).
New 52-week highTape · 2026-10-20
69.3x vol
Mixed: stocks have lagged random stocks by 0.9% over three sessions, not consistently enough to call (554 cases over 52 nights). Against their own sector they have lagged by 2.1%.
GappedTape · 2026-10-20
+125.6% ⚠ probable split/bad tick — the scanner believes this is a corporate action rather than a real move.
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Unusual volumeTape · 2026-10-20
164.1 sigma ⚠ probable split/bad tick — the scanner believes this is a corporate action rather than a real move.
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
GappedTape · 2026-10-14
-8.1%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Silence Therapeutics (SLN) Upgraded to Buy: Here's WhyZacks Investment Research · 2026-10-13

Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.

Insiders

No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.

What lines up

9 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy0
Buy1
Hold4
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray
3w · 1%

The most recent of 5 completed bases.

Checking your subscription…

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Silence Therapeutics Plc American Depository Share (SLN) — The Tape